Revive Therapeutics Files Business Acquisition Report
TORONTO, Feb. 08, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR) pursuant to National Instrument 51-102 Continuous Disclosure Obligations in connection with its acquisition of Psilocin Pharma Corp. on March 5, 2020. The BAR has been filed as a result of a review conducted by staff at the Ontario Securities Commission in connection with the Company’s recently filed preliminary short form prospectus dated January 26, 2021.
For more information, please contact:Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: [email protected]